SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 81.22 |
| Enterprise Value ($M) | -73.25 |
| Book Value ($M) | 154.49 |
| Book Value / Share | 3.14 |
| Price / Book | 0.53 |
| NCAV ($M) | 140.14 |
| NCAV / Share | 2.85 |
| Price / NCAV | 0.58 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.82 |
| Return on Assets (ROA) | -0.47 |
| Return on Equity (ROE) | -0.62 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 10.84 |
| Current Ratio | 10.84 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 178.35 |
| Assets | 192.69 |
| Liabilities | 38.20 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -106.96 |
| Net Income | -147.27 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -108.79 |
| Cash from Investing | 58.40 |
| Cash from Financing | -11.82 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Flynn James E | 3.78 | -52.98 | |
| 13G/A | Deep Track Capital, LP | 0.00 | -100.00 | |
| 13G | Tang Capital Partners Lp | 9.50 | ||
| 13D/A | Frazier Life Sciences Public Fund, L.P. | 21.40 | 8.50 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 24,868 | 104,638 | 23.77 | |
| 116,070 | 274,812 | 42.24 | |
| 37,245 | 213,832 | 17.42 | |
| 50,786 | 226,859 | 22.39 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| GLUE – Monte Rosa Therapeutics, Inc. | GOSS – Gossamer Bio, Inc. |
| HALO – Halozyme Therapeutics, Inc. | HOWL – Werewolf Therapeutics, Inc. |
| HUMA – Humacyte, Inc. |
Financial data and stock pages provided by
Fintel.io